Start with what we know

Every engagement starts by developing a deep understanding of the treatment landscape.

That means more than compiling approved therapies, clinical trials and competitor activity. Our therapeutic-area specialists bring experience from working within these markets and combine it with SAI’s competitive, clinical and commercial intelligence expertise.

That context matters.

It allows us to look at a landscape not simply as a snapshot of where the market is today, but as a dynamic environment: where standards of care could shift, where emerging evidence could change perceptions, how competitors could respond, and where the basis of differentiation may evolve.

We move from “What is happening?” to “What could happen next — and what would that mean for this asset?”

Find the questions that matter

Once we understand the landscape and the forces shaping it, the next step is identifying what we don’t know.

Not all intelligence gaps are equal.

Some unknowns are interesting but ultimately have little bearing on strategy. Others sit underneath critical assumptions about differentiation, positioning, development or commercial opportunity.

Our therapeutic-area and commercial experience helps us identify those assumptions, risks and intelligence gaps and translate them into the Key Intelligence Topics and Key Intelligence Questions that matter.

Before looking for answers, make sure you are asking the right questions.

Pressure-test what could be true

This is also where new technology is changing what is possible.

SAI’s Synthetic Users capability enables our experts to explore open questions rapidly, pressure-test assumptions and establish baseline hypotheses around potential competitive differentiation and pathways to commercial success.

The objective isn’t to replace primary intelligence — or human expertise — with AI. It is to make both more effective.

By exploring multiple questions and scenarios early, we can develop an initial view of where uncertainty remains greatest, which assumptions appear most important and where getting the answer wrong could have the greatest strategic or commercial consequence.

That creates a clearer basis for prioritization.

Instead of trying to investigate everything, teams can focus their time, resources and primary intelligence on the questions where greater certainty has the greatest potential value.

Take the questions that matter into the real world

The final step is targeted primary intelligence.

SAI combines deep clinical expertise and expert networks with extensive commercial intelligence capabilities, including the PharmaForce network, to investigate priority questions with the people closest to the market.

What are clinicians actually seeing? How are perceptions changing? How could competitors behave? Which scenarios are credible? Where does the initial hypothesis hold — and where does the real world challenge it?

Each new piece of intelligence can reduce uncertainty, challenge an assumption or uncover another question that needs to be explored.

Why we’re sharing our thinking

Our new therapeutic-area deep dives are an expression of this approach.

We could simply tell clients that we have deep expertise in areas such as AML and myelofibrosis. Instead, we want to show what that expertise looks like in practice.

We want to share what our teams are seeing in rapidly evolving treatment landscapes. The changes we think deserve attention. The assumptions we would challenge. The questions we believe are worth asking. And some of the ways we can begin exploring those questions.

Because ultimately, competitive and strategic intelligence shouldn’t be measured by the volume of information it produces.

Its value lies in helping teams distinguish signal from noise, understand what remains uncertain and focus intelligence resources where they can have the greatest impact on a decision.